Furthermore, we investigated whether seven weeks of POCU1b treatment attenuates obesity, NAFL, and IR using high-fat diet (HFD)-fed rats, by measuring the body weight, fat weight, adipocyte size, liver TG levels, and insulin sensitivity, and determining the mRNA or protein expression of (p)-AMPK and suppressor of cytokine signaling-3 (SOCS-3) in the liver. This evidence concerns the gene SOCS3 and obesity disorder.